Context: There has been interest in identifying whether nutrients might help optimize cognitive performance, especially for the military tasked with ensuring mission-readiness. Objective: This systematic review assesses the quality of the evidence for n-3 polyunsaturated fatty acids (PUFAs) across various outcomes related to cognitive function in healthy adult populations in order to develop research recommendations concerning n-3 PUFAs for mission-readiness. Data Sources: PubMed, CINAHL, Embase, PsycInfo, and the Cochrane Library were searched. Study Selection: Peer-reviewed randomized controlled trials published in the English language were eligible. Data Extraction: Thirteen included trials were assessed for methodological quality, and descriptive data were extracted. Data Synthesis: Of the acceptable-quality (n ¼ 8) and high-quality (n ¼ 1) studies, 2 produced no statistically significant results, 5 produced mixed results, and 2 did not report between-group results. Conclusions: Results indicate that ingestion of n-3 PUFAs does not significantly alter cognitive performance in cognitively healthy persons. Studies exposing subjects to adverse circumstances that would be most relevant for drawing conclusions specifically for the military population are lacking. Several research recommendations are offered to enhance understanding of the role of fatty acids on cognitive functioning.
INTRODUCTION
Although robust physical health has always been a core component of mission-readiness for combat, there is increasing emphasis on optimizing cognitive and emotional health among combat operators. 1 Military personnel perform extremely complex cognitive tasks, often under trying circumstances such as exposure to war-zone stressors, sleep deprivation, intense physical or mental exertion, and/or certain extreme environmental conditions. Such conditions might impair learning, reaction time, accuracy, vigilance, and complex decision making. [2] [3] [4] [5] [6] [7] [8] [9] To ensure optimal cognitive mission-readiness, it is imperative to determine whether and to what extent cognitive functioning can be enhanced to counter cognitive detriments due to exposure to these high-stress military situations.
In addition to the need for optimizing cognitive functioning in the war zone, it is essential to identify strategies that protect warfighters from postdeployment cognitive problems. Indeed, extended wartime operations in Iraq and Afghanistan have created significant challenges for the health of warfighters. Psychological trauma is common, with 15.1% of veterans returning with acute stress disorder, 5.3% with depression, and 5.6% with anxiety. 10 Depression and anxiety have been shown to reduce attention, memory, and executive function. 11 This highlights the importance of implementing preventive measures that encourage cognitive and emotional health as means to promote resilience against the effects of trauma. One potential opportunity for optimizing cognitive functioning during deployment and preventing cognitive impairment after deployment is dietary supplementation. Dietary interventions can be introduced during the extensive training for combat and can, possibly, be carried forward during and after deployment.
Omega-3 (n-3) polyunsaturated fatty acids (PUFAs) have been shown to have positive effects on cognitive performance across a number of different populations and outcomes. [12] [13] [14] [15] [16] [17] Research has demonstrated improvement for children in some areas of cognition, behavior, and school performance, 18 for infants in their cognitive development, 19 and for subsets of aging populations, with or without cognitive impairment, in cognitive function. 20, 21 Further, evidence is growing that n-3 PUFAs may be specifically beneficial to people who have incurred a mild traumatic brain injury due to the neuroprotective function of n-3 PUFAs. 13 Preloading soldiers with n-3 PUFAs may play a preventive role against cognitive impairment and improve cognitive outcomes. 22 A small body of evidence exists on the efficacy of n-3s in brain recovery and neuron regeneration, and this evidence indicates that preloading troops before combat may have a protective role in reducing the impact of traumatic brain injury (TBI) and other combat-related injuries. Increased consumption of fatty acids, particularly preloading, may also have a positive impact on cognitive performance; however, clinical trials do not currently exist on this topic. 23 Further, studies have shown an association between low n-3 levels and the likelihood of suffering from depressive illness. 23 Because depression and anxiety are correlated with reduced attention, memory, and executive function, 11 researchers argue that improving depression through increased n-3 PUFA consumption may result in improved cognitive performance. 24 To the extent that n-3 fatty acids have these effects, enhancing the diets of soldiers in training, during deployment, and following deployment with n-3 fatty acids may be worthwhile.
A military expert panel released a paper in 2014 recommending increased intake of n-3 PUFAs for service members, noting that existing research indicated promising effects on mission-readiness and in benefitting TBI patients. 23 However, at that time, n-3 PUFAs were not among the supplements most commonly used by service members. 25 In fact, US service members have been shown to have lower levels of n-3s than their civilian counterparts, possibly due to low n-3 content in food rations. 22 Further, a recent survey of service members found the average intake of eicosahexaenoic acid (EPA) and docosahexaenoic acid (DHA) sources to be 301 mg/day, 26 which is below the suggested intake of 500 mg per day recommended by the American Dietetic Association. 27 The ramifications of low n-3 PUFA intake on cognitive performance in healthy military personnel, particularly those exposed to high-stress military situations, are unknown. Recommendations might become policy to the extent that the literature is clear with respect to the effects of n-3 PUFAs on cognitive performance, but at this moment there is no information about the effect of n-3 PUFAs in military personnel. Other questions, such as the optimal amount of n-3 PUFAs when exposed to suboptimal conditions common in the military, and what kind of outcome assessments are most sensitive for the factors that matter most to readiness, have also not been defined. The purpose of this systematic review was to determine whether there is enough objective evidence to support the recommendations of increased intake of n-3 PUFAs for enhancing cognitive brain function in the otherwise healthy warfighter and to offer recommendations based on gaps that currently exist in the literature, specifically for the military.
METHODS
The aims of this particular review were to (1) assess the evidence for the quantity, quality, and efficacy of n-3 PUFAs across the various outcomes related to cognitive function in the healthy adult population; (2) describe the characteristics and safety as reported in each included study; (3) perform an analysis of what the present authors believe are the essential reporting criteria for studies involving nutritional elements as interventions; (4) provide an overall synthesis and interpretation of the evidence in order to draw initial conclusions for the military population; and (5) identify research gaps to guide a future research agenda. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses standard reporting guidelines were followed for this systematic review. A steering committee (SC) and subject matter experts (SMEs) convened to develop the protocol and define the research question, as well as to synthesize the overall evidence gathered through the systematic review. 28 The criteria used to define the research question are presented in Table 1 ; the population, intervention, comparison, outcomes, and study design strategy was used.
Literature search strategy
The following databases were searched from their inception through January 2014: PubMed, CINAHL, Embase, PsycInfo, and Cochrane (Clinical Trials). Searches were limited to peer-reviewed randomized controlled trials (RCTs) presented in the English language. ( The complete details are reported in an accompanying article within this supplement). 28 Using the predefined study eligibility criteria described in another article within this supplement, 28 4 investigators (S.A., J.B., H.C., and M.O.) independently screened titles and abstracts of the citations yielded from the literature search. This was done in duplicate, first for the purpose of scoping the literature in accordance with the larger effort to identify the relevant dietary interventions to investigate, 29 and second for the specific identification of RCTs on n-3 PUFAs for the purpose of this review (Table 1) .
Quality assessment and data extraction
The Mobius Analytics Systematic Review System (Mobius Analytics Inc., Ottawa, ON, Canada) was used for all data entry and execution of the systematic review. Six investigators reviewed all articles meeting eligibility criteria in duplicate. All conflicts were tracked and resolved through consensus meetings or by consulting the SMEs. Articles meeting the review's predefined inclusion criteria were assessed for methodological bias and quality using the Scottish Intercollegiate Guidelines Network (SIGN) 50 Checklist at the study level. 30 An analysis of the following 4 criteria was also conducted at the intervention level: (1) preparation of food(s), diets, or supplements used in the intervention; (2) baseline/background diet; (3) control of diet during the intervention; and (4) content analysis of the intervention. 28 This analysis is referred to as the Standards for Reporting Interventions in Controlled Trials Essential to Nutritional Elements (STRICT-NE), a reporting checklist proposed to improve reporting standards and facilitate transparency and reproducibility in studies involving nutritional elements. 31, 32 Descriptive data were also extracted to describe the characteristics and safety as reported in the included studies.
Data synthesis
A formal meta-analysis was not feasible due to the heterogeneity found across studies and among the various outcome metrics reported in the included studies. Instead, an expert panel was convened with the SMEs and SC to review the evidence gathered from the systematic review in order to develop conclusions and to research recommendations based on the gaps that emerged from the review using a modified Grading of Recommendations, Assessment, Development, and Evaluation approach. 33 The full methodology for this review is detailed in another article within this supplement. 28 
RESULTS

Selection of articles and study characteristics
Of the 7051 articles yielded from the broad search strategy, 13 RCTs that examined the effect of n-3 PUFAs on cognitive function among healthy adult populations were identified and included in this systematic review. For the broader research question aimed at identifying other dietary interventions relevant for military readiness, 28 63 other studies and 1 of the studies within this review 34 met the eligibility criteria. Those studies are detailed in 3 additional systematic reviews found within this supplement and are outlined in Figure S1 in the Supporting Information online).
35-37
The 13 studies reporting on n-3 PUFAs were published between 2000 and 2013 and involved a total of 2290 healthy adults (16.6% male; 42.6% female; 40.8% not described), with an age range of 18-80 years. None of the included studies exposed participants to militarylike moderators 28 such as sleep deprivation, physical Peer-reviewed randomized controlled trial published in the English language exertion, heat stress, or cold stress. Twelve studies compared !1 n-3 supplement groups with a placebo control, 34, [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] and the remaining study used a normal diet as control. 49 Two studies involved >1 n-3 PUFA arms to examine a dose response. 38, 42 An additional study compared DHA plus lutein with lutein alone. 34 Among the 13 studies, 9 studies involved varying ratios of DHA and EPA, [38] [39] [40] [41] [42] [43] 45, 47, 48 2 studies involved DHA alone, 34, 44 and 2 studies involved DHA and EPA combined with other types of n-3 and n-6 PUFAs. 46 , 49 The reported cognitive function outcomes were subcategorized into memory, verbal fluency, attention and vigilance, simple and complex reaction time, psychomotor performance, and problem solving and reasoning. The majority of studies assessed cognitive outcomes at baseline and post-intervention ( Table 2) .
Quality assessment
According to the SIGN 50 criteria used to assess methodological bias, 1 study was rated as high-quality [þþ], 8 were rated as acceptable-quality [þ], and 4 were rated as low-quality [0]. The majority of studies adequately addressed an appropriate and clearly focused question, percentage of dropouts, blinding, baseline similarities, and group differences. Randomization and intentionto-treat analyses were largely poorly addressed across the 13 studies. Allocation concealment was either poorly or adequately addressed by an equal number of studies, and the remaining study addressed this criteria well. Validity of outcome measures was either well covered or adequately addressed by an equal number of studies and the remaining study did not address this criteria well. One study 40 was conducted at multiple sites and addressed multisite comparability poorly (Table S1 in the Supporting Information online).
Standards for reporting interventions in controlled trials essential to nutritional elements analysis
A STRICT-NE analysis was conducted to determine whether authors described essential reporting criteria for nutritional intervention studies. 31, 32 An analysis based on the 4 STRICT-NE criteria is provided below, as well as in Table S2 in the Supporting Information online.
All 13 of the included studies reported on the methods by which the nutritional intervention was prepared, including delivery method (n ¼ 13), preparer of the intervention (n ¼ 11), and source of n-3 PUFAs (n ¼ 12). All studies delivered the intervention in capsule form. In 11 studies, the capsules were commercially produced and encapsulated by various third parties. 34, [38] [39] [40] [41] [44] [45] [46] [47] [48] [49] The other 2 studies did not report on who produced or encapsulated the treatments. 42, 43 Of the 13 studies, 11 reported using fish oil and 1 used microalgae Crypthecodinium cohnii as a source of n-3 PUFAs. 44 The remaining study did not report the source of n-3 PUFAs used. 34 Information about the subjects' diets prior to enrollment in the study was reported with varying degrees of detail in 10 of the 13 studies. 34, [38] [39] [40] [41] [42] [43] [44] [45] 47 This included assessing the subjects' entire diets, including fish consumption (n ¼ 2 studies) 39, 47 and assessing solely the amount of fish and/or fish supplements consumed (n ¼ 8 studies). 38, 41, 43, 44 Reasons for assessing background diet were to exclude subjects taking fish-based supplements or consuming large amounts of fish (n ¼ 8), 34, [39] [40] [41] [42] [43] [44] [45] estimate fish intake in the 3 months prior to the study (n ¼ 1), 38 and record the subjects' regular diet (n ¼ 1). 47 Six of 13 studies reported on whether the subjects' background diets were controlled during the duration of the study. 34, 41, [45] [46] [47] [48] Methods included maintaining the subjects' regular diets (n ¼ 2); 34, 47 maintaining the subjects' regular intake of n-3s PUFAs, but refraining from caffeinated substances 4 hours before testing (n ¼ 1); 48 maintaining the subjects' regular diets with the exception of avoiding fatty fish or fish oil supplements (n ¼ 1) 45 or limiting intake of fish (n ¼ 1); 41 and employing a dietician to develop personalized diets for the subjects to "avoid excesses." 46 Only 2 of the 13 studies reported whether the contents of the intervention were analyzed to assess whether they contained the intended amount of n-3 PUFAs being reported. One study used the mean of 20 samples taken over the course of the study to assess the EPA-DHA content of the capsules; 38 however, the analytical method applied was not reported. The other study used gas chromatography to analyze the fatty-acid content of the capsules. 45 It was unclear whether an independent third party conducted these analyses.
Funding source
Twelve studies provided information on the funding source: 6 34, 41, 42, 44, 48, 49 were classified as industry sponsored with or without academic and government collaboration, 3 were funded by government grants, 38-40 and 3 were funded by private research entities. 43, 45, 47 Safety and adverse events Of the 13 included studies, 2 studies reported that no adverse events occurred during the study, 46 ,47 6 studies did not mention or provide any information on adverse events, 34, 39, [41] [42] [43] 48 and 1 study reported that adverse events occurred but did not describe the nature of those events. 49 The remaining 4 studies, which involved a combined total of 1397 participants, reported adverse events and described them. 38, 40, 44, 45 The most common category of adverse events was gastrointestinal, which occurred in both the intervention and the placebo arms.
Other categories reported included urogenital, women's health, musculoskeletal, dermatological, and minor adverse events (eg, restlessness, weight gain, feeling lifeless, and blurred vision) ( Table 2) .
Results according to cognitive function outcome
The evidence for n-3 PUFAs was evaluated according to each cognitive function outcome subcategorized as relevant to military mission-readiness (See Table 2 and Table S3 in the Supporting Information online for complete details according to each study included.).
Memory. Nine studies, which involved a combined total of 2110 healthy adults, examined the effects of n-3 PUFAs on memory. Overall, the effect of PUFAs on memory was largely not significant. The 1 study determined to be of high-quality did not find any significant differences for memory between 1800 mg or 400 mg of EPA-DHA versus placebo. 38 Of the 6 acceptable-quality studies, the first 2 studies did not find any significant differences between EPA-DHA versus placebo. 40 , 43 The third study found mixed results, reporting favorably for n-3 PUFAs on 1 of 2 tasks compared with placebo. 45 The fourth study 41 reported that both EPA-rich and DHA-rich interventions had worse performances compared with placebo for 1 of the 5 tasks. The final 2 studies only reported within-group results: in the first study, 34 the DHA plus lutein arm showed significant improvements in 2 of the 3 memory tasks over time, whereas no changes occurred in the other 3 arms (DHA only, lutein only, and placebo); the second study found no significant within-group differences in either the EPA-DHA or placebo groups. 39 Of the 2 low-quality studies, 1 study found no significant differences between EPA-DHA and placebo on several memory outcomes, 48 whereas the second study had mixed results. 44 Verbal fluency. Four studies, which involved a combined total of 1366 healthy subjects, examined the effects of PUFAs on verbal fluency. Results for these studies were largely not significant. The 1 high-quality study 38 and 2 acceptable-quality 40, 41 studies found no significant differences in treatment effect when comparing PUFAs to placebo. The third acceptable-quality study only reported within-group results and found all 3 treatment groups (DHA, lutein, and lutein plus DHA) achieved significantly better fluency compared with baseline, whereas the placebo group did not. 34 Attention and vigilance. Eleven studies, which involved a combined total of 2208 healthy subjects, collected data on attention-related outcomes. Among the 1 highquality and 6 acceptable-quality studies, between-group results were statistically not significant, with some results trending toward n-3 PUFAs compared with placebo. The high-quality study found no significant differences between 1800 mg or 400 mg of EPA-DHA versus placebo. 38 The acceptable-quality studies found few significant treatment effects. Two studies found no significant between-group differences, 40,43 whereas 3 studies found some significant treatment effects in favor of n-3 PUFAs versus placebo; results for a majority of tasks were statistically not significant. 41, 42, 45 An additional study reporting only within-group results found no significant changes from baseline for all study arms. 34 The 4 remaining low-quality studies reported mixed results. 44, [46] [47] [48] Simple reaction time. Seven studies, which involved a combined total of 1560 healthy subjects, examined the effects of n-3 PUFAs on simple reaction time. Of the 4 acceptable-quality studies, 3 compared n-3 PUFAs with placebo, [40] [41] [42] and 1 compared n-3 PUFAs with the subjects' normal diets. 49 None of these studies found significant differences between groups for simple reaction time. The 3 low-quality studies also reported no statistically significant results. 44, 46, 48 Complex reaction time. Nine studies, which involved a combined total of 1844 healthy subjects, reported the effects of n-3 PUFAs on complex reaction time. Results for the 6 acceptable-quality studies were mixed. Two studies found no significant differences between n-3 PUFAs and placebo. 40, 41 One found a significant treatment effect in favor of EPA-rich capsules versus normal diet, 49 and 2 studies found n-3 PUFA groups had greater improvements compared with the placebo group on 1 of 2 complex reaction time tasks.
42, 45 The final study reported no significant interaction effects of time Â treatment in either the EPA-DHA or placebo groups. 39 Within the 3 low-quality studies, no significant results were reported. 44, 46, 48 Psychomotor performance. Two studies, which involved a combined total of 345 healthy subjects, examined the effect of n-3 PUFAs on psychomotor performance. Neither the 1 high-quality study 38 nor the 1 acceptablequality 43 study comparing EPA-DHA with placebo found any significant differences between groups.
Problem solving and reasoning. Three studies, which involved a combined total of 402 healthy subjects, reported the effects of n-3 PUFAs on problem solving and reasoning. Results were mixed but largely in favor of placebo. The 1 high-quality study found no statistically significant differences between 1800 mg or 400 mg of EPA-DHA and placebo. 38 Results for the 2 acceptablequality studies indicated placebo outperformed n-3 PUFAs: 1 study reported a significant within-group increase in response speed in the placebo group but not the DHA, DHA plus lutein, or lutein groups; 34 the other study reported the n-3 PUFAs group performed significantly worse than the placebo group. 43 
DISCUSSION
Overall evidence synthesis
This systematic review revealed that across cognitive outcomes the majority of studies examined showed no statistically significant findings for n-3 PUFAs in otherwise healthy adults. None of the studies captured in this review exposed participants to military-like moderators (ie, stressors such as sleep deprivation, extreme environmental factors, or physical exertion), which limits the generalizability of findings to the military population of interest. In general, safety was not well reported for this group of studies. For each subgroup analysis and synthesis at the outcome level, the SC and SMEs agreed that further research would likely have an important impact on the level of confidence in the estimate of effect, and no recommendations can be made at this time concerning any benefits or risks for using n-3 PUFAs to help optimize cognitive performance. Whereas otherwise healthy people tended to stay healthy during the n-3 PUFA interventions, the question of whether the ingestion of n-3 PUFAs could help enhance cognitive brain function for those exposed to military-like moderators remains unanswered (Table 3) .
Strengths and limitations
This review contains limitations. First, the systematic review includes only RCTs published in the English language as a means to uncover the evidence base. Although no RCT studies were identified that exposed subjects to military-like moderators, it could be that long-term observational research trials and epidemiological studies may be more helpful in answering questions about the effects of prolonged n-3 PUFAs consumption patterns over years and decades. Preloading service members with n-3 PUFAs before deployment may be a specific research interest of the military. Such a practice could serve a role in brain recovery after mild traumatic brain injury, as well as positively impact cognitive performance. 23 However, evaluating the benefits and risks of n-3 PUFA preloading for mild traumatic brain injury was outside the scope of this review.
Second, because this review focuses on the optimization of cognitive brain function of healthy service members in order to increase military readiness, it included studies that only involved healthy populations. The evidence evaluated revealed that healthy populations' cognitive performance, as being measured in the included studies, does not significantly change when supplemental n-3 PUFAs are given. It is not the intent of this review to address other conditions commonly present in military subpopulations, such as anxiety, depression, concussions and other traumas, pain, and post-traumatic stress. However, there appears to be sparse research in this area; a post-hoc analysis revealed only 2 studies that passed the initial screening involving depression and comparing the effect of PUFAs to placebo on cognitive performance. Both studies 50, 51 found no significant differences between groups for cognitive function.
Third, since this systematic review was originally conducted, new research has been conducted that fits within the scope and inclusion criteria. An RCT 52 that involved an older population in their 70s found no significant differences in cognitive function among those who received long-chain polyunsaturated fatty acids versus those who did not. Another RCT, 53 which compared n-3 PUFAs versus placebo in healthy young adults, found no significant effect on mood, cognition, or physiological stress markers regardless of whether subjects were exposed to a stressor. These results are consistent with the findings reported throughout this review.
Gaps in the literature and research recommendations for the field
This systematic review revealed several research gaps. First, and most important, none of the studies that fit the inclusion criteria involved military personnel or subjects exposed to military-like moderators. Objective data from the RCT studies reviewed do not support increasing n-3 PUFAs in the diet to help optimize cognitive performance. Future studies involving the effect of essential PUFAs (n-3 and n-6) and their delivery methods (pill vs ingestion in food) on cognitive performance under these stressed circumstances in a military-like setting would be needed.
Second, a large variety of cognitive outcome tools are being used, which makes it impossible to conduct meta-analyses by combining results across studies. Rarely were the same cognitive tools used in >3 studies. The SC and SMEs recommend investigating which validated tools are the most sensitive for use in future research so cognitive outcome tools can be standardized for studies within the military and for research at large. Without this, objective evidence to support any recommendations will remain a gap. Additionally, for human performance optimization, validated cognitive outcome tools are needed to differentiate state changes and to discriminate low from mid-range to high normal performance.
Third, when evaluating study design methodology, a number of SIGN 50 criteria were consistently poorly reported, including randomization, concealment, and intention-to-treat analysis. It is important for researchers to abide by Consolidated Standards of Reporting Trials 54 reporting guidelines, which emphasize the importance of these criteria and offer researchers a standard approach to use when preparing reports of trial findings, to facilitate complete and transparent reporting, and to aid in critical appraisal and interpretation. Refers to the likelihood that future research will change the confidence in the estimate of the effect, adapted from the GRADE Working Group approach. 33 A, high confidence in the estimate of the effect; B, moderate confidence in the estimate of the effect; C, low confidence in the estimate of the effect; D, very low confidence in the estimate of the effect. b From þ2 (appears safe with infrequent adverse events) to À2 (appears to have serious safety concerns, including frequent and serious adverse events). c Options are: strong recommendation in favor of or against (ie, very certain that benefits do, or do not, outweigh risks and burdens); no recommendation (ie, evidence is lacking to make any recommendation); or weak recommendation in favor or against (benefits and risks and burdens are finely balanced, or appreciable uncertainty exists about the magnitude of benefits and risks).
Fourth, various types of control/comparators for the supplement treatment were used across these studies, which makes it challenging to pool studies and synthesize the evidence base. Implementing the use of appropriate controls and comparators is recommended. Soy, coconut, sunflower, and olive oil were used as placebo controls across studies. Each contained different fats and essential fatty acids profiles and may have exerted differing physiologic effects. The SC and SMEs recommend developing a standard placebo comprised of 80% soy and 20% palm oil that mimics the ratio of fat found in the standard American diet.
Fifth, none of the included studies reported controlling the amount of n-6 fatty acid consumed during the duration of the study. Omega-3 and n-6 PUFAs compete for metabolic resources within shared pathways. 55 The dietary balance of n-3s to n-6s may be important to cognitive performance. 55 Research has shown that subjects with higher intake and tissue levels of n-6 compared with n-3 are more susceptible to cardiovascular disease, depression, and diminished wound healing. 56 The SC and SMEs recommend that future studies focus on the effect of n-6/n-3 ratios on cognition in adult populations exposed to conditions common to the military.
Relevance beyond the military and future research recommendations
The present authors intended for this review to address the strength of the RCT data on dietary n-3 PUFAs to help optimize warfighter cognitive performance. The recommendations for future research presented in Box 1 support that end state. Yet, this kind of knowledge would be applicable widely to other populations including shift workers and others that do strenuous work under surge situations, like firefighters, search-and-rescue workers, and disaster responders. Unfortunately, the relevant research has not yet been conducted.
CONCLUSION
Results of the current systematic review evaluating RCT study designs revealed that healthy populations consuming additional n-3 PUFAs do not significantly improve in terms of cognitive performance, but they tend to stay healthy during the interventions. An expert panel that was convened to interpret the evidence gathered in this review, concluded that, given this evidence, no recommendations for the use of n-3 PUFA supplements for any cognitive outcomes in otherwise healthy populations could be made. Objective evidence gained from exposing research participants to military stressors will be needed in order to generalize results for the military and, specifically, for enhancing mission-readiness. To support recommendations for increasing the intake of n-3 PUFAs for the military, additional research is required within this particular population.
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Investigate the delivery methods for n-3 PUFAs appropriate to the phases of the military deployment cycle.
Conduct long-term observational research trials and epidemiological studies to further understand ranges of chronic intake of the essential PUFAs with regard to health outcomes.
Standardize cognitive outcome tools relevant to the military population across the range of military operations, and identify those capable of detecting effects above the threshold of disease or disability into the range of superior performance.
Improve the methodological quality and reporting for future studies.
Determine appropriate placebo controls for PUFAs intervention studies.
Institute. All recommendations set forth were made collectively by the Steering Committee, subject matter experts, and Samueli Institute during the expert roundtable and are based on the results of the systematic review gaps that emerged.
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